Payment overview · 2025
General Payments
$1,388.30
58 reported records · 17 companies
Healthcare provider profile · identity verified
Amanda Cooper, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WINNSBORO, SC · NPI 1952073827
Verified facts
What the public records show
CMS Open Payments records show Amanda Cooper, NP received $1,388.30 in general payments during 2025 across 58 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $514.60 | 37.1% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $162.44 | 11.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $157.71 | 11.4% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $152.20 | 11.0% | 11 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $105.14 | 7.6% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $49.87 | 3.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.70 | 2.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.84 | 2.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.71 | 2.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.25 | 1.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.82 | 1.6% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.87 | 1.5% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.17 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.52 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.01 | 1.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.77 | 1.1% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $15.68 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,388.30 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $307.18 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $224.94 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $133.75 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $133.75 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $124.93 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $105.14 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $93.69 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $63.18 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.52 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $49.87 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.51 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.70 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $31.84 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $28.71 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.45 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.05 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 133 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 126 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 93 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 40 |
| Fluconazole | Fluconazole | 90 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 78 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 28 |
| Lisinopril | Lisinopril | 68 | 21 |
| Montelukast Sodium | Montelukast Sodium | 68 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 22 |
| Famotidine | Famotidine | 61 | 18 |
| Azithromycin | Azithromycin | 57 | 53 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Omeprazole | Omeprazole | 51 | 19 |
| Gabapentin | Gabapentin | 50 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 49 | 19 |
| Losartan Potassium | Losartan Potassium | 48 | 20 |
| Furosemide | Furosemide | 44 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 21 |
| Allopurinol | Allopurinol | 36 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 14 |
| Tramadol Hcl | Tramadol Hcl | 32 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 16 |
| Nystatin | Nystatin | 30 | 21 |
| Trazodone Hcl | Trazodone Hcl | 29 | 15 |
| Meloxicam | Meloxicam | 28 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 24 |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | 14 |
| Colchicine | Colchicine | 26 | 12 |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Metformin Hcl | Metformin Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Prednisone | Prednisone | 18 | 16 |
| Cephalexin | Cephalexin | 17 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 14 |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 12 |
| Cimetidine | Cimetidine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,388.30 · 58 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BEYFORTUS, BREZTRI, CAPLYTA, CLOTTRIEVER BOLD CATHETER, Dexcom G6 Transmitter, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Korlym, MOUNJARO, NUPLAZID, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error